Daniel Linden
Overview
Explore the profile of Daniel Linden including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1237
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Armisen J, Rauschecker M, Sarv J, Liljeblad M, Wernevik L, Niazi M, et al.
J Hepatol
. 2025 Jan;
PMID: 39798707
Background & Aims: A common genetic variant (rs738409) encoding isoleucine to methionine at position 148 in the PNPLA3 protein is a determinant of hepatic steatosis, inflammation, fibrosis, cirrhosis, and liver-related...
2.
Ciociola E, Dutta T, Sasidharan K, Kovooru L, Noto F, Pennisi G, et al.
Clin Mol Hepatol
. 2024 Dec;
PMID: 39716370
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a global epidemic. MASLD has a strong genetic component, and a common missense variant (rs2642438) in the mitochondrial amidoxime-reducing component 1 (MARC1)...
3.
Linden D, Tesz G, Loomba R
Liver Int
. 2024 Nov;
45(4):e16186.
PMID: 39605307
Metabolic dysfunction-associated steatotic liver disease (MASLD) is caused by metabolic triggers and genetic predisposition. Among the genetic MASLD risk variants identified today, the common PNPLA3 148M variant exerts the largest...
4.
Paskoff K, Matz B, Fournier Q, Aisa J, Oblak M, Bray J, et al.
Vet Comp Oncol
. 2024 Nov;
23(1):37-41.
PMID: 39496580
Carotid body paragangliomas represent an uncommon neoplasm in dogs. The objective of this study was to report outcomes and complications associated with surgical excision of carotid body paragangliomas in 21...
5.
Dutta T, Sasidharan K, Linden D, Romeo S
Liver Int
. 2024 Jun;
44(8):2093-2094.
PMID: 38888208
No abstract available.
6.
Vacca M, Kamzolas I, Harder L, Oakley F, Trautwein C, Hatting M, et al.
Nat Metab
. 2024 Jun;
6(6):1178-1196.
PMID: 38867022
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, encompasses steatosis and metabolic dysfunction-associated steatohepatitis (MASH), leading to cirrhosis and hepatocellular carcinoma. Preclinical MASLD research is...
7.
Johnson S, Bao H, McMahon C, Chen Y, Burr S, Anderson A, et al.
Nat Commun
. 2024 Jun;
15(1):4847.
PMID: 38844467
The I148M variant of PNPLA3 is closely associated with hepatic steatosis. Recent evidence indicates that the I148M mutant functions as an inhibitor of PNPLA2/ATGL-mediated lipolysis, leaving the role of wild-type...
8.
Liu K, Lazaro-Ibanez E, Lerche M, Linden D, Salvati A, Sabirsh A
Nat Commun
. 2024 May;
15(1):3853.
PMID: 38724506
No abstract available.
9.
Dutta T, Sasidharan K, Ciociola E, Pennisi G, Noto F, Kovooru L, et al.
Liver Int
. 2024 Feb;
44(5):1219-1232.
PMID: 38375985
Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a global health concern with no effective and specific drug treatment available. The rs2642438 minor allele in mitochondrial amidoxime-reducing component 1 (MARC1)...
10.
Johnson S, Bao H, McMahon C, Chen Y, Burr S, Anderson A, et al.
bioRxiv
. 2023 Sep;
PMID: 37693552
Summary Statement: We define the physiological role of wild type PNPLA3 in maintaining hepatic VLDL-TG secretion.